

at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at <http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 21, 2010.

Jill Hartzler Warner,

Acting Associate Commissioner for Special Medical Programs.

[FR Doc. 2010-27008 Filed 10-25-10; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; HIV/AIDS Behavioral Treatment Intervention and Services Development-Member Conflict.

Date: November 12, 2010.

Time: 9:30 a.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call)

Contact Person: Enid Light, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Boulevard, Room 6132, MSC 9608, Bethesda, MD 20852, 301-443-3599, elight@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award;

93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: October 18, 2010.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-26959 Filed 10-25-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Council of Councils, November 8, 2010, 9 a.m. to November 8, 2010, 3 p.m., National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892 which was published in the **Federal Register** on September 30, 2010, 75 FR 60465.

This **Federal Register** Notice is amended to add a Closed Session from 12:15 p.m. to 12:45 p.m. on November 8, 2010.

The meeting is partially closed to the public.

Dated: October 20, 2010.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-27051 Filed 10-25-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Listing of Members of the National Centers for Disease Control and Prevention's 2010 Performance Review Board (PRB)

AGENCY: The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC) announces the persons who will serve on the CDC's 2010 Performance Review Board. This action is being taken in accordance with Title 5, U.S.C., 4314(c)(4), which requires that members of performance review boards be appointed in a manner to ensure consistency, stability, and objectivity in performance appraisals and requires

that notice of the appointment of an individual to serve as a member be published in the **Federal Register**.

The following persons will serve on the CDC Performance Review Board, which is responsible for making recommendations on performance appraisal ratings, pay adjustments, and performance awards for CDC's Senior Executive Service (SES) members:

Kevin Fenton (Co-Chair), Lynn Austin (Co-Chair), Ed Hunter, Rima Khabbaz, Crayton Lankford, Carolyn Black, Christine Branche, Anne Haddix, Barbara Harris, Jim Seligman, Walter Harris, Hazel Dean, Bill Porter.

For further information about the CDC Performance Review Board, contact the Centers for Disease Control and Prevention, Human Capital Management Office, Human Capital Planning Branch, 1600 Clifton Road, NE., MS E-50, Atlanta, GA 30333. Telephone (404) 498-6709 (not a toll free number).

Dated: October 20, 2010.

Tanja Popovic,

Deputy Associate Director for Science, Centers for Disease Control and Prevention.

[FR Doc. 2010-26999 Filed 10-25-10; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0511]

Withdrawal of Approval of New Animal Drug Applications; Aklomide; Levamisole Hydrochloride; Nitromide and Sulfantran

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of eight new animal drug applications (NADAs). In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to remove portions reflecting approval of these NADAs.

DATES: Withdrawal of approval is effective November 5, 2010.

FOR FURTHER INFORMATION CONTACT: John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, e-mail: john.bartkowiak@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, a Division of Wyeth Holdings, a Wholly Owned Subsidiary of Pfizer, Inc., 235 East 42d

St., New York, NY 10017 has requested that FDA withdraw approval of the eight NADAs listed in Table 1 of this document.

TABLE 1

| NADA No. | Product | Established name of drug(s) |
|-------------------|---|--------------------------------------|
| NADA 11-141 | UNISTAT-2 Type A medicated article | nitromide and sulfantran |
| NADA 14-250 | NOVASTAT Type A medicated article | aklomite and sulfantran |
| NADA 34-536 | ALKOMIX Type A medicated article | aklomite |
| NADA 34-537 | ALKOMIX-3 Type A medicated article | aklomite, sulfantran, and roxarsone |
| NADA 35-388 | NOVASTAT-3 Type A medicated article | aklomite, sulfantran, and roxarsone |
| NADA 39-666 | NOVASTAT-W Soluble Powder | aklomite and sulfantran |
| NADA 44-015 | UNISTAT-3 Type A medicated article | nitromide, sulfantran, and roxarsone |
| NADA 45-455 | TRAMISOL Type A medicated article | levamisole |
| NADA 45-455 | TRAMISOL Type A medicated article | levamisole |

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADAs 11-141, 14-250, 34-536, 34-537, 35-388, 39-666, 44-015, and 45-455, and all supplements and amendments thereto, is hereby withdrawn, effective November 5, 2010.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: October 8, 2010.

Bernadette Dunham,

Director, Center for Veterinary Medicine.

[FR Doc. 2010-27010 Filed 10-25-10; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-5382-N-16]

Notice of Proposed Information Collection for Public Comment: Survey of Market Absorption of New Multifamily Units

AGENCY: Office of Policy Development and Research, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for approval as required by the Paperwork Reduction Act of 1995. The Department is soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* December 27, 2010.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to

the proposal by name/or OMB Control Number and should be sent to: Reports Liaison Officer, Office of Policy Development and Research, Department of Housing and Urban Development, 451 7th Street SW., Room 8234, Washington, DC 20410.

FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the proposed forms and instructions submitted to OMB should be directed to: Carolyn Lynch, Economist, Housing and Demographic Analysis Division, Office of Policy Development and Research, Department of Housing and Urban Development, 451 7th Street, SW., Washington, DC 20410; via telephone (202) 402-5910 (this is not toll-free number); via e-mail at Carolyn.Lynch@hud.gov or to Robert R. Callis, U.S. Census Bureau, Social, Economic and Housing Statistics Division, 4600 Silver Hill Road, Room 7H087, Washington, DC 20233; via telephone (301) 763-5694 (this is not toll-free number); via e-mail at Robert.R.Callis@Census.gov.

SUPPLEMENTARY INFORMATION: The Department of Housing and Urban Development will submit the proposed information collection package to OMB for review as required by the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35, as amended).

I. Abstract: Description of the Need for the Information and Proposed Use

The Survey of Market Absorption (SOMA) provides the data necessary to measure the rate at which new rental apartments and new condominium apartments are absorbed; that is, taken off the market, usually by being rented or sold, over the course of the first twelve months following completion of a building. The data are collected at quarterly intervals until the twelve months conclude, or until the units in a building are completely absorbed. The survey also provides estimates of certain characteristics, including asking rent/

price, number of units, and number of bedrooms. The survey provides a basis for analyzing the degree to which new apartment construction is meeting the present and future needs of the public. Additionally, beginning with new construction in 2002, the survey ascertains the number and degree of services provided by "Assisted Living" type units.

II. Method of Collection

The methodology for collecting information on the lease or sale of new multifamily units involves contacting a sample of new multifamily units by telephone or in person.

III. Data

Title of Proposal: Survey of Market Absorption of New Multifamily Units.

OMB Control Number: 2528-0013 (Expires 1/30/2011).

Form Number: H-31.

Type of Review: Regular Submission.
Members of affected public: Rental Agents/Builders.

Estimated Number of Respondents: 12,000 yearly (maximum).

Estimated Time per Response: 20 minutes.

Frequency of Response: Four times (maximum).

Estimated Total Annual Burden Hours: 4,000 (12,000 × 20 minutes).

Estimated Total Annual Cost: The only cost to respondents is that of their time. The total estimated cost to do the survey in FY 2011 is \$943,000.

Respondent's Obligation: Voluntary.

Legal Authority: The survey is taken under Title 12, United States Code, Section 1701Z.

IV. Request for Comments

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed information collection of information to: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the